Twitter Logo Youtube Circle Icon LinkedIn Icon

The Legal 500 Hall of Fame Icon The Legal 500 Hall of Fame highlights individuals who have received constant praise by their clients for continued excellence. The Hall of Fame highlights, to clients, the law firm partners who are at the pinnacle of the profession. In Europe, Middle East and Africa, the criteria for entry is to have been recognised by The Legal 500 as one of the elite leading lawyers for seven consecutive years. These partners are highlighted below and throughout the editorial.
Click here for more details

Switzerland > Legal Developments > Law firm and leading lawyer rankings

Editorial

Bär & Karrer Advises Lonza on the Entering into a Strategic Joint Venture with Chr. Hansen for Deve

On 2 April 2019, Lonza, a leading pharma contract manufacturing company, and Chr. Hansen, a leading global bioscience company, announced that they have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland. A phased investment of approximately EUR 90 million will be deployed over three years to build cGMP-compliant pharma production capabilities. The joint venture will upgrade existing facilities in Hørsholm (DK) and equip new facilities in Basel (CH) to serve pre-clinical to phase II projects. Further facilities for phase III and commercial manufacturing will be developed as the pipeline matures. The joint venture is expected to be largely self-funding after the production set-up has been established.

Bär & Karrer acts as legal advisor to Lonza. The team includes Urs Kägi, Nadina Duss, Michael Bänziger, Matthias Tanner (all M&A/Corporate and Commercial) and Markus Wang (IP).

On 2 April 2019, Lonza, a leading pharma contract manufacturing company, and Chr. Hansen, a leading global bioscience company, announced that they have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland. A phased investment of approximately EUR 90 million will be deployed over three years to build cGMP-compliant pharma production capabilities. The joint venture will upgrade existing facilities in Hørsholm (DK) and equip new facilities in Basel (CH) to serve pre-clinical to phase II projects. Further facilities for phase III and commercial manufacturing will be developed as the pipeline matures. The joint venture is expected to be largely self-funding after the production set-up has been established.

Bär & Karrer acts as legal advisor to Lonza. The team includes Urs Kägi, Nadina Duss, Michael Bänziger, Matthias Tanner (all M&A/Corporate and Commercial) and Markus Wang (IP).

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

International Law Firm Networks

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

GC Powerlist -
Europe

International Law Firm Networks